.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Citi
Moodys
Novartis
Chubb
Argus Health
Fuji
Boehringer Ingelheim
Queensland Health
Deloitte

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,435,498

« Back to Dashboard

Which drugs does patent 8,435,498 protect, and when does it expire?


Patent 8,435,498 protects FINACEA and is included in one NDA. There has been one Paragraph IV challenge on Finacea.

This patent has one hundred and thirty-three patent family members in nineteen countries.

Summary for Patent: 8,435,498

Title:Penetrating pharmaceutical foam
Abstract: The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.
Inventor(s): Tamarkin; Dov (Maccabim, IL), Friedman; Doron (Karmei Yosef, IL), Eini; Meir (Ness Ziona, IL)
Assignee: Foamix Ltd. (Rehovot, IL)
Application Number:12/752,718
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
FINACEA
azelaic acid
AEROSOL, FOAM;TOPICAL207071-001Jul 29, 2015RXYesYes► Subscribe► Subscribe TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,435,498

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel152486Oct 25, 2002

Non-Orange Book Patents for Patent: 8,435,498

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,795,635Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses► Subscribe
8,703,105Oleaginous pharmaceutical and cosmetic foam► Subscribe
8,518,378Oleaginous pharmaceutical and cosmetic foam► Subscribe
2,010,040,561► Subscribe
9,492,412Penetrating pharmaceutical foam► Subscribe
9,050,253Oleaginous pharmaceutical and cosmetic foam► Subscribe
9,713,643Foamable carriers► Subscribe
7,704,518Foamable vehicle and pharmaceutical compositions thereof► Subscribe
7,820,145Oleaginous pharmaceutical and cosmetic foam► Subscribe
8,900,554Foamable composition and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,435,498

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office2422768► Subscribe
European Patent Office2097065► Subscribe
European Patent Office2257276► Subscribe
European Patent Office2029106► Subscribe
European Patent Office2051697► Subscribe
European Patent Office2073794► Subscribe
European Patent Office1556009► Subscribe
European Patent Office1663148► Subscribe
European Patent Office1670435► Subscribe
European Patent Office1699433► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Mallinckrodt
Colorcon
Chinese Patent Office
Covington
Dow
Cerilliant
Julphar
Teva
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot